Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (31-40 of 153) with videos related to

Pageof 16
Sort By:
Haematologica|July 2, 2002
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology oneGiovanni Martinelli, Marilina Amabile, Barbara Giannini, et al.
Haematologica|November 19, 2013
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemiaFabio Efficace, Gianantonio Rosti, Neil Aaronson, et al.
Clinical Chemistry|April 27, 2004
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to ImatinibSimona Soverini, Giovanni Martinelli, Marilina Amabile, et al.
Critical Reviews in Oncology/Hematology|December 5, 2017
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panelMartin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, et al.
Haematologica|July 18, 2009
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri, Fausto Castagnetti, Simona Soverini, et al.
Expert Opinion on Drug Safety|May 31, 2018
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinibMassimo Breccia, Fabio Efficace, Alessandra Iurlo, et al.
Leukemia|March 26, 2022
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemiaMichele Baccarani, Francesca Bonifazi, Simona Soverini, et al.
Haematologica|March 26, 2003
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemiaGianantonio Rosti, Elena Trabacchi, Simona Bassi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2013
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemiaMario Arpinati, Giulia Tolomelli, Maria Teresa Bochicchio, et al.
Expert Review of Hematology|November 25, 2010
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd studyFrancis J Giles, Gianantonio Rosti, Photis Beris, et al.
Pageof 16

Showing results (31-40 of 153) with videos related to

Sort By:
Pageof 16
Haematologica|July 2, 2002
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology oneGiovanni Martinelli, Marilina Amabile, Barbara Giannini, et al.
Haematologica|November 19, 2013
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemiaFabio Efficace, Gianantonio Rosti, Neil Aaronson, et al.
Clinical Chemistry|April 27, 2004
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to ImatinibSimona Soverini, Giovanni Martinelli, Marilina Amabile, et al.
Critical Reviews in Oncology/Hematology|December 5, 2017
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panelMartin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, et al.
Haematologica|July 18, 2009
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failureFrancesca Palandri, Fausto Castagnetti, Simona Soverini, et al.
Expert Opinion on Drug Safety|May 31, 2018
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinibMassimo Breccia, Fabio Efficace, Alessandra Iurlo, et al.
Leukemia|March 26, 2022
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemiaMichele Baccarani, Francesca Bonifazi, Simona Soverini, et al.
Haematologica|March 26, 2003
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemiaGianantonio Rosti, Elena Trabacchi, Simona Bassi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2013
Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemiaMario Arpinati, Giulia Tolomelli, Maria Teresa Bochicchio, et al.
Expert Review of Hematology|November 25, 2010
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd studyFrancis J Giles, Gianantonio Rosti, Photis Beris, et al.
Pageof 16